

DAFTAR PUSTAKA

1. Nair PA, Singhal R. Xanthelasma palpebrarum – a brief review. *Clinical, Cosmetic and Investigational Dermatology*. 2018; 11: 1-5.
2. Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma palpebrarum clinical and biochemical profile in a tertiary care hospital of Delhi. *Indian Journal of Clinical Biochemistry*. 2007; 22(2): 151-3.
3. Marcelo GH, Janis PM. Xanthelasma. 2005. <http://www.eMedicineSpecialties>. – Diakses Oktober 2018.
4. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: Clinical and pathophysiological relations. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic*. 2014; 158(2): 181-8.
5. James WD, Berger TG, Elston DM, editors. Lipid disturbances. Xanthomatosis. In: *Andrew's Diseases of The Skin, Clinical Dermatology*. WB Saunders. 2009; 10: 530-6.
6. Hon C, Leok G, Ket N, Hoon T. Cosmetic dermatology. In: *Asian skin; a reference color atlas of dermatology and venereology*. McGraw Hill Education. 2014; 2: 462-4.
7. Christoffersen M, Frikke-Schmidt R, Schnor P, Jensen GB, Nordestgaard BG, Tybjaerg Hansen A. Xanthelasma, arcus corneae, and ischaemic vascular disease and death in general population: Prospective cohort study. *British Medical Journal*. 2011; 343.
8. Aggarwal R, Rathore PK. A study evaluating xanthelasma palpebrarum clinically and biochemically. *International Journal of Contemporary Medical Research*. 2016; 3(9): 2565-7.
9. Dahl AA. Xanthelasma. *Drug and Disease: Ophtalmology*. 2017.
10. Kavoussi H, Rezaei M, Najafi B, Ebrahimi A, Ramezani M, Kavoussi R. Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum. *Anais Brasileiros de Dermatologia*. 2016; 91(4): 468-71.
11. Lee HY, Jin US, Minn KW, Park YO. Outcomes of surgical management of xanthelasma palpebrarum. *Archives of Plastic Surgery*. 2013; 40: 380-6.
12. Rao W, Su Y, Yang G, Ma Y, Liu R, Zhang S, et al. Cross-sectional associations between body mass index and hyperlipidemia among adults in Northeastern China. *International Journal of Environmental Research and Public Health*. 2016; 13(516): 1-10.
13. Heng JK, Chua SH, Goh CL, Cheng S, Tan V, Tan WP. Treatment of xanthelasma palpebrarum with 1064 nm, Q switched Nd: YAG laser. *Journal of The American Academy of Dermatology*. 2017: 1-7.

14. Park EJ, Youn SH, Cho EB, Lee GS, Hann SKg, Kim KH, et al. Xanthelasma palpebrarum treatment with a 1450 nm diode laser. *American Society for Dermatologic Surgery*. 2011; 37: 791-6.
15. Savitha MR, Sandeep B. The study of lipid profile, diet and other cardiovascular risk factors in children born to parents having premature ischemic heart disease. *Indian Journal of Community Medicine*. 2011; 36(4): 291-6.
16. Biadgo B, Abebe SM, Baynes HW, Yesuf M, Alemu A, Abebe M. Correlation between serum lipid profile with anthropometric and clinical variables in patients with type 2 diabetes mellitus. *Ethiopian Journal of Health Sciences*. 2017; 27(3): 215-26.
17. Schaefer EJ, Santos RD. Xanthomatoses and lipoprotein disorders. In: *Skin in Nutritional, Metabolic, and Heritable Disease*, 2003; 24(135): 1600.
18. Flynn PD. Xanthomas and abnormalities of lipid metabolism and storage. In: *Metabolic and Nutritional Disorders*. 2016; 59(103): 59-81.
19. Massengale WT, et al. Xanthomas. *Disorders Due to Physical Agents*. 2014; 14: 1411.
20. Govorkova MS, Milman T, Ying GS, Pan W, Silkiss RZ. Inflammatory mediators in xanthelasma palpebrarum: Histopathologic and immunohistochemical study. *Ophthalmologic Plastic Reconstructive Surgery*. 2017; 20(20): 1-5.
21. Laftah Z, et al. Xanthelasma: An update on treatment modalities. *Journal of Cutaneous and Aesthetic Surgery*. 2018; 11: 1-6.
22. Dianawaty A, Adam AM. Xanthelasma dan milia. In: Amiruddin MD, editor. *Tumor dan Bedah Kulit*. Makassar: Bagian Ilmu Penyakit Kulit dan Kelamin. Fakultas Kedokteran Universitas Hasanuddin. 2013.
23. Habif TP. Xanthoma and dislipoproteinemia. In: *Clinical Dermatology: A Color Guide to Diagnosis and Therapy*. United State: Mosby. 2004; 902-3.
24. Ozdol S, Sahin S, Tokgozoglu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein. *International Journal of Dermatology*. 2008; 47(8): 785-9.
25. Lippincott W, Wilkins, Elder DE. Xanthomas associated with lipid abnormalities. In: *Lever's Histopathology of the Skin*. Philadelphia. 2009: 680-6.
26. Youn SJ, Park HS, Kim WS, Lee ES, Yang JM. Bilateral xanthelasma palpebrarum on both eyelids in a 9-years-old boy. *Pediatric Dermatology*. 2006; 23(1): 95-7.
27. Rohrich RJ, Janis JE, Downell PH. Xanthelasma palpebrarum: a review and current management principles. *Plastic and Reconstructive Surgery*. 2002; 110: 1310-4.
28. Taylor SR, Perone JB, Kaddu S, Kerl H. Appendage tumors and hamartomas of the skin. In: Wolff K, Freedberg IM, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS,

et al., editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: Mc Graw-Hill Companies; 2008. 1268-87.

29. Juneja M, Chougale Q, Abhyankar S. Rare and unusual presentation of periorbital xanthelasma. *Journal of Dermatology and Dermatologic Surgery*. 2016; 20: 149-51.
30. Basar E, Oguz H, Ozdemir H, Ozkan S, Uslu H. Treatment of xanthelasma palpebrarum with argon laser photocoagulation. *International Ophthalmology*. 2004; 25(1): 9-11.
31. Knott L. Xanthelasma. Patient Platform Limited. 2016: 1-2. patient.info/doctor/xanthelasma. – Diakses Oktober 2018.
32. Adhitya P. Hubungan antara indeks massa tubuh (IMT) dengan nilai lemak visceral. *Jurnal Media Medika Muda*, Fakultas Kedokteran, Universitas Diponegoro. 2014.
33. Karsai S, Schmitt L, Raulin C. Is Q-switched neodymium-doped yttrium aluminium garnet laser an effective approach to treat xanthelasma palpebrarum? Results from a clinical study of 76 cases. *Dermatologic Surgery*. 2009; 35(12): 1962-9.
34. Idrus MS. *Multivariate data analysis & nonparametrik statistik* Ed.1. Surabaya: Zifatama Publisher. 2013; 44-7.
35. Ren J, Zeng LY, Chen MH. Treatment of grade I and II types of xanthelasma palpebrarum with intralesional heparin sodium. *Wiley Dermatologic Therapy*. 2018;1: 1-3.
36. Pathania V, Chatterjee M. Ultrapulse carbon dioxide laser ablation of xanthelasma palpebrarum: a case series. *Journal of Cutaneous and Aesthetic Surgery*. 2015;8(1):46-9.
37. Rolfes. Weight management: overweight, obesity, and underweight. In: Peggy W, Elisha F, Alexis G, Lauren T, editors. *Understanding Nutrition*. 2013; 12: 270-310.
38. White LE. Xanthomatoses and lipoprotein disorder. In: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, et al. *Fitzpatrick's Dermatology in General Medicine* Ed.7. New York: McGraw-Hill. 2008; 135: 1272-81.
39. Borelli C, Kaudewitz P. Xanthelasma palpebrarum: treatment with the erbium: YAG laser. *Lasers in Surgery and Medicine*. 2001; 29: 260-4.
40. Rao W, Su Y, Yang G, Ma Y, Liu R, Zhang S, et al. Cross-sectional associations between body mass index and hyperlipidemia among adults in Northeastern China. *International Journal of Environmental Research and Public Health*. 2016; 13(16): 1-10.
41. Kim J, Kim YJ, Hyoseob L, Se IL. Bilateral circular xanthelasma palpebrarum. *Archives of Plastic Surgery*. 2012; 39(4):435-7.

42. Admira P, Sayuti K. Xantelasma dan arkus kornea juvenilis sebagai manifestasi *familial hypercholesterolemia*. Jurnal Kesehatan Andalas. 2018; 7(3):125-30.
43. Pietroleonardo L, Ruzicka T. Skin manifestation in familial heterozygous hypercholesterolemia. Acta Dermato-Venereologica. 2009; 18: 183-7.
44. Chitra U, Reddy NK, Balakrishna N. Role of lifestyle variables on the lipid of selected south Indian subjects. Indian Heart Journal. 2012: 28-34.
45. Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV. Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgraduate Medical Journal. 2012; 88(1038): 198-204.
46. Tursen U, Eskandari G, Kaya TI, Tamer L, Ikizoglu G, Atik U. Apolipoprotein polymorphism and lipoprotein compositions in normolipidaemic xanthelasma patients. Journal of the European Academy of Dermatology and Venereology. 2006; 20: 260-3.
47. Sahin S, Tokgozoglu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein. International Journal of Dermatology. 2008; 47: 785-9.
48. Fusade T. Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd: YAG laser: a study of 11 cases. British Journal of Dermatology. 2008; 158: 84-7.
49. Wulandari N, Nilasari H, Cipto H. Xantelasma, gambaran klinis dan penatalaksanaan. Departemen Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokteran Universitas Indonesia. 2013; 40(1): 46-55.

